Marathi | HIndi

Epaper
Follow us:
Home > International > US approves single-dose Johnson & Johnson COVID-19 vaccine for emergency use
US approves single-dose Johnson & Johnson COVID-19 vaccine for emergency use English.Lokmat.com

US approves single-dose Johnson & Johnson COVID-19 vaccine for emergency use

The United States authorised Johnson & Johnson's COVID-19 vaccine for emergency use on Saturday, adding a third vaccine to the US arsenal to fight the pandemic as the death toll due to the infection crosses 5.11 lakh.
US approves single-dose Johnson & Johnson COVID-19 vaccine for emergency use

The United States authorised Johnson & Johnson's COVID-19 vaccine for emergency use on Saturday, adding a third vaccine to the US arsenal to fight the pandemic as the death toll due to the infection crosses 5.11 lakh.

It is the first single-dose Covid-19 vaccine available in the US, and is one that "checks nearly all the boxes", CNN reported.

The US Food and Drug Administration (FDA) approved the nation's third coronavirus vaccine. The official emergency use authorization for Johnson & Johnson's (J&J) single-dose vaccine comes after an FDA advisory panel voted 22-0 to recommend authorization on Friday.

The United States has reported more than 28.5 million confirmed Covid-19 cases and over 511,000 reported deaths. The demand of vaccines still far exceeds supply, these vaccines can't come soon enough.

"A third safe and effective vaccine is very welcome news," Andy Slavitt, the White House's senior for Covid Response, tweeted on Friday.

The vaccine, made by Janssen, J&J's vaccine arm, is safe and effective, and it's considered flexible. It's a single dose, and it doesn't require special storage.

The vaccine is authorized for people ages 18 and older.

"We need a vaccine that can be quickly mass-produced," Dr Greg Poland, head of the Mayo Clinic's Vaccine Research Group, said Friday. "We'd want to see a reasonable duration of efficacy and protection.

"The Janssen vaccine candidate checks nearly all the boxes."

The vaccine was tested in more than 44,000 people in the US, South Africa, and Latin America. Globally, it was 66.1 percent effective against moderate to severe/critical Covid-19 at least four weeks after vaccination, according to an FDA analysis.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

US approves single-dose Johnson & Johnson COVID-19 vaccine for emergency use
France reports nearly 24,000 new COVID-19 cases
Saudi-led coalition intercepts ballistic missile attack towards Riyadh: Report
Al-Qaeda linked Turkish group expanding its network in Nepal: Report
Al-Qaeda linked Turkish group expanding its network in Nepal: Report